| Literature DB >> 30413193 |
Yaoju Tan1, Biyi Su1, Wei Shu2, Xingshan Cai1, Shaojia Kuang1, Haobin Kuang1, Jianxiong Liu3, Yu Pang4.
Abstract
BACKGROUND: Pulmonary nontuberculous mycobacteria (NTM) disease is of increasing public health concern in China. Information is limited regarding risk factors associated with this disease in China. The objective of this study was to describe the epidemiology of pulmonary disease due to NTM in Southern China.Entities:
Keywords: Comorbidity; Epidemiology; Nontuberculous mycobacteria; Rapidly growing mycobacteria; Slowly growing mycobacteria
Mesh:
Substances:
Year: 2018 PMID: 30413193 PMCID: PMC6230232 DOI: 10.1186/s12890-018-0728-z
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Fig. 1Distribution of nontuberculous mycobacteria species isolated from pulmonary NTM patients in South China
Comparison in demographic and clinical characteristics of NTM patients between slowly growing mycobacteria and rapidly growing mycobacteria at Guangzhou Chest Hospital, China, January 1, 2013 to December 31, 2017
| Characteristics | No. of pulmonary NTM cases (%) | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| SGM | RGM | OR (95% CI) | OR (95% CI) | |||
| Gender | ||||||
| Female | 170 (49.4) | 171 (65.0) | 0.526 (0.378–0.731) | < 0.001 | 0.608 (0.429–0.862) | 0.005 |
| Male | 174 (50.6) | 92 (35.0) | 1.000 | – | 1.000 | – |
| Age group (years) | ||||||
| 18–40 | 34 (9.9) | 53 (20.2) | 1.000 | – | 1.000 | – |
| 40–60 | 122 (35.5) | 106 (40.3) | 0.557 (0.337–0.922) | 0.023 | 0.488 (0.287–0.827) | 0.008 |
| > 60 | 188 (54.7) | 104 (39.5) | 0.355 (0.217–0.581) | < 0.001 | 0.395 (0.235–0.666) | < 0.001 |
| TB history | ||||||
| No | 149 (43.8) | 96 (36.5) | 1.000 | – | ||
| Yes | 195 (57.4) | 167 (63.5) | 1.329 (0.953–1.852) | 0.093 | ||
| Population | ||||||
| Residence | 168 (48.8) | 89 (33.8) | 1.000 | – | 1.000 | – |
| Migration | 176 (51.2) | 174 (66.2) | 1.855 (1.331–2.585) | < 0.001 | 1.551 (1.092–2.202) | 0.014 |
| Diabetes | ||||||
| No | 328 (95.3) | 252 (95.8) | 1.000 | – | ||
| Yes | 16 (4.7) | 11 (4.2) | 0.895 (0.408–1.962) | 0.895 | ||
| Bronchiectasis | ||||||
| No | 158 (45.9) | 93 (35.4) | 1.000 | – | 1.000 | – |
| Yes | 186 (54.1) | 170 (64.6) | 1.553 (1.116–2.16) | 0.009 | 1.521 (1.064–2.176) | 0.021 |
| COPD | ||||||
| No | 326 (94.8) | 256 (97.3) | 1.000 | – | ||
| Yes | 18 (5.2) | 7 (2.7) | 0.495 (0.204–1.204) | 0.121 | ||
| Tumor | ||||||
| No | 321 (93.3) | 251 (95.4) | 1.000 | – | ||
| Yes | 23 (6.7) | 12 (4.6) | 0.667 (0.326–1.367) | 0.269 | ||
SGM slowly growing mycobacteria, RGM rapidly growing mycobacteria, COPD chronic obstructive pulmonary disease, OR odds ratio, 95% CI 95% confidence interval
Comparison of in vitro drug susceptibility profiles between M. intracellulare and M. avium isolates
| Antimicrobial agents | No. of resistant isolates (%) | ||
|---|---|---|---|
|
|
| ||
| Clarithromycin | 4 (4.2) | 6 (3.8) | 1.000 |
| Moxifloxacin | 5 (5.3) | 8 (5.0) | 1.000 |
| Linezolid | 11 (11.6) | 13 (8.2) | 0.370 |
The breakpoints to establish susceptibility and resistance for clarithromycin, moxifloxacin and linezolid were followed as recommendation from Clinical and Laboratory Standards Institute (CLSI-M24-A2)
Comparison of in vitro drug susceptibility profiles between M. abscessus subspecies abscessus and M. abscessus subspecies massiliense isolates
| Antimicrobial agents | No. of resistant isolates (%) | ||
|---|---|---|---|
|
| |||
| Amikacin | 3 (2.2) | 2 (2.1) | 1.000 |
| Clarithromycin | 6 (4.4) | 3 (3.2) | 0.740 |
| Linezolid | 6 (4.4) | 2 (2.1) | 0.476 |
| Tobramycin | 6 (4.4) | 2 (2.1) | 0.476 |
| Cefoxitin | 46 (33.8) | 24 (25.3) | 0.164 |
| Ciprofloxacin | 86 (63.2) | 68 (71.6) | 0.186 |
| Doxycycline | 127 (93.4) | 94 (98.9) | 0.050 |
| Imipenem | 134 (98.5) | 95 (100.0) | 1.000 |
The breakpoints to establish susceptibility and resistance for drugs were followed as recommendation from Clinical and Laboratory Standards Institute (CLSI-M24-A2)